Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥1,247 JPY
Change Today +1.00 / 0.08%
Volume 105.8K
As of 2:00 AM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

r-tech ueno ltd (4573) Snapshot

Open
¥1,249
Previous Close
¥1,246
Day High
¥1,254
Day Low
¥1,244
52 Week High
03/9/15 - ¥2,324
52 Week Low
05/21/14 - ¥945.00
Market Cap
24.1B
Average Volume 10 Days
210.7K
EPS TTM
¥51.99
Shares Outstanding
19.3M
EX-Date
03/27/15
P/E TM
24.0x
Dividend
¥30.00
Dividend Yield
2.41%
Current Stock Chart for R-TECH UENO LTD (4573)

Related News

No related news articles were found.

r-tech ueno ltd (4573) Related Businessweek News

No Related Businessweek News Found

r-tech ueno ltd (4573) Details

R-Tech Ueno, Ltd. is engaged in the research, development, manufacture, and sale of pharmaceutical products for the treatment of ophthalmology and dermatology worldwide. The company offers Rescula eye drops to treat glaucoma and ocular hypertension. Its product pipeline comprises Rescula/UF-021, which is in Phase IIb clinical trials to treat retinitis pigmentosa; RU-101 which is in Phase IIa clinical trials for the treatment of dry eye; and RK-023 that is in Phase IIa clinical trials to treat alopecia, as well as in Phase I clinical trials to treat hypotrichosis of the eyelashes. The company is also developing RTU-007 for treating diabetic cataract and retinopathy, and age-related macula degeneration; RTU-1096 for the treatment of atopic dermatitis, contact dermatitis, psoriasis, and diabetic neuropathy. In addition, it offers R and D assistance services, including development of synthetic methods; contract manufacturing of pharmaceuticals; characterization studies; formulation studies; and quality tests and stability tests for drug substances and drug products. Further, the company is engaged in contract manufacturing of injections, eye drops, liquid drugs, liquid-filled hard capsules, solid formulations, and ointments. R-Tech Ueno, Ltd. was founded in 1989 and is headquartered in Tokyo, Japan.

75 Employees
Last Reported Date: 06/25/14
Founded in 1989

r-tech ueno ltd (4573) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

r-tech ueno ltd (4573) Key Developments

R-Tech Ueno Announces the End of a Phase 3 Clinical Study with Unoprostone (Development Code UF-021) Ophthalmic Solution

R-Tech Ueno announced the end of a Phase 3 clinical study with Unoprostone (development code UF-021) ophthalmic solution that are being developed in company for the treatment of retinitis pigmentosa and the preliminary Findings from a Phase 3. The Phase 3 clinical study with UF-021 ophthalmic solution for treatment of retinitis pigmentosa, for which an effective therapy has not been currently established, was a multicenter study using a placebo (without the active ingredient) as a control carried out based on Good Clinical Practice in patients with visual field constriction and then deterioration of vision. This was a randomized double-masked controlled study for 52 weeks for efficacy, followed by the open trial study of UF-021 for a further 52 weeks for safety. The target sample size was 180 patients and the study was carried out at 38 sites nationwide. The primary endpoint of the study was the changes in the value of the mean retinal sensitivity at four central points through HFA (10-2). The difference compared to the placebo group was not statistically significant. However, the primary endpoint and visual acuity of UF-021 group demonstrated improvement compared to Day 0 (before the study) and the difference was statistically significant. On the other hand, the Goldmann visual field of the placebo group progressed statistically and significantly the constriction of the visual field compared to Day 0. Furthermore the total score of VFQ-25 was found to have improved statistically and significantly in the UF-021 group. The company confirmed the therapeutic effectiveness of UF-021 ophthalmic solution for Retinitis Pigmentosa through the present Phase 3 clinical study in Japan, but as the primary endpoint at the end of study was not statistically significant, the company is analyzing the data from various angles and examining possibility of the new drug application to MHLW as best it can now. And the company decided to close the open trial study of UF-021 for a further 52 weeks for safety in the view of objectivity of the data obtained.

R-Tech Ueno, Ltd. Announces Consolidated Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014; Provides Earnings Guidance for the Fiscal Year Ending March 31, 2015; Expects to Pay Year End Dividend for the Fiscal Year Ending March 31, 2015

R-Tech Ueno, Ltd. announced consolidated earnings results for the third quarter and nine months ended December 31, 2014. For the nine months, the consolidated company reported net sales of ¥4,272 million, operating income of ¥862 million, ordinary income of ¥1,013 million, net income of ¥754 million or net income per diluted share of ¥38.78 compared to net sales of ¥4,213 million, operating income of ¥1,082 million, ordinary income of ¥1,158 million, net income of ¥813 million or net income per diluted share of ¥41.83 for the same period last year. Net sales increased 1.4% year on year, mainly due to the brisk domestic sales of AMITIZA® Capsule and the increased revenue of AMITIZA® Capsule for the US market underpinned by Yen depreciation. For the quarter, the company reported net sales of ¥1,543 million, operating income of ¥450 million, ordinary income of ¥550 million and net income of ¥397 million compared to net sales of ¥1,418 million, operating income of ¥368 million, ordinary income of ¥403 million and net income of ¥280 million for the same period last year. In this third quarter, net sales has increased year-on-year, however, profit has decreased year-on-year due to an increase in research and development expenses associated with the progress of the UF-021 development. The company expected to pay year end dividend of ¥3.00 per share for the fiscal year ending March 31, 2015 compared to ¥25.00 per share for the same period last year. The company expects net sales of ¥6,639 million, operating income of ¥2,109 million, ordinary profit of ¥2,261 million, net income of ¥1,627 million or net income per share of ¥84.34 for the fiscal year ending March 31, 2015.

Sucampo Pharmaceuticals, Inc. and R-Tech Ueno, Ltd. Enter License Agreement with Par Pharmaceutical

Sucampo Pharmaceuticals, Inc. and R-Tech Ueno, Ltd. have entered into a stipulation and license agreement with Par Pharmaceutical, Inc. Under the terms of the agreement, in limited circumstances, Sucampo or RTU will grant PPI a license for a generic version of the RESCULA(R) (unoprostone isopropyl ophthalmic solution) 0.15% product approved for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension prior to the latest expiration date of the patents, which is July 2021. Under such license, PPI will split with Sucampo the gross profits of the generic or authorized generic version sold during the term of the agreement, which continues until the last of Sucampo patents relating to RESCULA have expired. In the event PPI elects to launch an authorized generic, Sucampo will supply PPI under the terms of a manufacturing and supply agreement at a negotiated price.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4573:JP ¥1,247.00 JPY +1.00

4573 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4573.
View Industry Companies
 

Industry Analysis

4573

Industry Average

Valuation 4573 Industry Range
Price/Earnings 24.3x
Price/Sales 4.3x
Price/Book 2.2x
Price/Cash Flow 23.8x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact R-TECH UENO LTD, please visit www.rtechueno.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.